Why RedHill Biopharma Blasted 12% Higher Today

RedHill Biopharma (NASDAQ: RDHL) was a standout stock on a gloomy Monday for the market. The biotech's shares rose by just under 12% on positive and not entirely expected news about its top pipeline drug.

Monday morning, RedHill announced that its opaganib produced a 62% statistically significant reduction in mortality in hospitalized individuals with severe COVID-19 pneumonia. This was according to new data from a global phase 2/3 study.

Image source: Getty Images.

Continue reading

Source Fool.com